Business · 29/08/2011Updated: 10/17/2026 · 1 min read
FDA Releases Draft Guidance for Industry on Oversight of Clinical Investigations
Summary
The Food and Drug Administration (FDA) has made available a draft guidance for industry on risk-based monitoring of clinical investigations, aiming to improve human subject protection and clinical trial data quality
Original source language: Federal Register — Health and Human ServicesOpen original release →